91��Ƶ

91��Ƶ Launches Rivaroxaban Tablets USP, 2.5mg in the United States

91��Ƶ Secures a Place in the Prestigious S&P Global Sustainability Yearbook 2025

91��Ƶ Receives EIR from U.S. FDA for its Somerset Manufacturing Facility

91��Ƶ Receives “A-” Leadership Rating from CDP in Two Categories – Climate Change and Water Security

91��Ƶ and Natco Receive Approval from U.S. FDA for Bosentan Tablets for Oral Suspension

91��Ƶ Receives Tentative Approval from U.S. FDA for Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide Tablets

Lupin Announces Closure of Inspection by U.S. FDA at its Somerset Facility with No Observations

91��Ƶ Receives Tentative Approval from U.S. FDA for Loteprednol Etabonate Ophthalmic Gel

91��Ƶ Receives EIR from U.S. FDA for its Pithampur Unit-1 Facility with VAI Classification